Avidity Biosciences excels in antibody oligonucleotide conjugates with its stock tripling in the past year due to innovative ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

A UCL study found that lamotrigine is as effective as mexiletine for treating non-dystrophic myotonia, a rare muscle disorder ...

Aging societies and population decline have been on the rise globally. However, the factors that correlate with population ...

This latest research on non-dystrophic myotonia offers promising results for those affected by the condition. Published in ...

A study tested the effectiveness of mexiletine and lamotrigine in treating non-dystrophic myotonia. Results indicated that ...

Lamotrigine, commonly used for epilepsy and mood disorders, has shown promise as a treatment for non-dystrophic myotonia, a ...

A common drug used to treat epilepsy and certain mood disorders, called lamotrigine, has shown great promise as a new ...

Mumbai: Global pharma major, Lupin Limited has announced that its subsidiary Lupin Atlantis Holdings SA has entered into a ...

The study, published in Lancet Neurology , detailed the "head-to-head" trial implemented by the researchers to test two drugs ...

Lamotrigine, a drug used for epilepsy and mood disorders, was found to be a good treatment for a rare muscle disease called ...

Celnova will commercialise NaMuscla in Argentina and Colombia, for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders ...